Key result
Stent thrombosis prevention research targets genomics and antiplatelet variability to identify high-risk patients.
Why the study?
Little advance has been made in outcomes following stent thrombosis, motivating research to better understand predictive factors, frequency, and timing in different patient subsets.
Stent thrombosis remains a significant challenge with ongoing research focused on predictive factors, genomics, antiplatelet response variability, and optimal prevention strategies.
Antiplatelet therapies retain their established preventive role; leaves open refinement via genomics and predictive factors in future studies.
Intense investigation continues on the pathobiology of stent thrombosis (ST) because of its morbidity and mortality. Because little advance has been made in outcomes following ST, ongoing research is focused on further understanding predictive factors as well as ST frequency and timing in various patient subsets, depending upon whether a drug-eluting stent or bare-metal stent has been implanted. Although the preventive role of antiplatelet therapies remains unchallenged, new data on genomics and variability in response to antiplatelet therapy, as well as the effects of novel therapeutic agents and duration of therapy, have become available. The goal remains identification of patients at particularly increased risk of ST so that optimal prevention strategies can be developed and employed.
No takes yet. Share an insight, caveat, or question.
Holmes et al. (2010) conducted a review in Stent thrombosis. Ongoing research on stent thrombosis focuses on predictive factors, genomics, and antiplatelet therapy response variability to identify high-risk patients and develop optimal prevention strategies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: